The estimated Net Worth of Zafrira Avnur is at least $177 Тысяча dollars as of 26 March 2018. Ms. Avnur owns over 2,000 units of Eloxx Pharmaceuticals Inc stock worth over $1 and over the last 7 years she sold ELOX stock worth over $0. In addition, she makes $177,100 as Independent Director at Eloxx Pharmaceuticals Inc.
Zafrira has made over 2 trades of the Eloxx Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of ELOX stock worth $18,980 on 26 March 2018.
The largest trade she's ever made was buying 2,000 units of Eloxx Pharmaceuticals Inc stock on 26 March 2018 worth over $18,980. On average, Zafrira trades about 323 units every 1 days since 2018. As of 26 March 2018 she still owns at least 2,263 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Ms. Avnur stock trades at the bottom of the page.
Zafrira Avnur serves as Independent Director of the Company. She has served as a member of our Board since December 2017, and previously served as a member of the board of directors of Eloxx Pharmaceuticals, Ltd. (the “Eloxx Limited Board”) since June 2017. Dr. Avnur is the Chief Scientific Officer at Quark Venture Inc., a venture investment fund focused on life sciences investments. Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering from 2009 until October 2016. Dr. Avnur was also named Global Head of Neglected Diseases Roche Partnering from 2010 until 2012. She also has created nine startup companies and serves on the board of directors of several portfolio companies. Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC (Personalized Health Care) initiative. Prior to her partnering roles, Dr. Avnur worked in diagnostics and pharmaceuticals research and development for nearly 20 years. She held a number of positions progressing from scientist and manager to global responsibilities. In these roles she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds. Dr. Avnur received a B.Sc. in Biology and a M.Sc. in Biology from Ben Gurion University and a Ph.D. in Immunology from the Weizmann Institute of Science. Dr. Avnur also conducted post-doctoral work at Stanford Medical Center in the Cancer Immunology Department.
As the Independent Director of Eloxx Pharmaceuticals Inc, the total compensation of Zafrira Avnur at Eloxx Pharmaceuticals Inc is $177,100. There are 2 executives at Eloxx Pharmaceuticals Inc getting paid more, with Gregory Williams having the highest compensation of $2,690,850.
Zafrira Avnur is 68, she's been the Independent Director of Eloxx Pharmaceuticals Inc since 2017. There are no older and 11 younger executives at Eloxx Pharmaceuticals Inc.
Zafrira's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC, 480 ARSENAL WAY, SUITE 130, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv и Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: